Articles related to CAR T-CELL THERAPIES

“By disabling Ant2, we triggered a complete shift in how T cells produce and use energy. This reprogramming made them significantly better at recognizing and killing cancer cells.”

“This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.” — Norman Sharpless, MD

Despite poor prognosis at treatment initiation, extended follow-up reveals sustained remissions suggesting curative potential in heavily pretreated CLL patients receiving CD19-directed cellular immunotherapy.

T cell activation by dietary proteins provides a previously unknown mechanism for tumor suppression in the small intestine, with significant implications for clinical nutrition protocols.

The study’s findings highlight the complex interplay between CAR T cell therapy and cytokine signaling in AML treatment, suggesting new avenues for improving outcomes in this challenging disease.

Lisocabtagene maraleucel offers a new treatment option for patients with CLL who have progressed on both BTK and BCL2 inhibitors, addressing an important unmet need in this patient population.